Escalating therapy in steroid-refractory relapses of multiple sclerosi
Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption
What it found
We found no results in the registry or in papers.
What was tested
Compared with
- Methylprednisolone
Glucocorticoid receptor agonist
What it measured
Main measures
Primary efficacy endpoint: EDSS on day 45 or before start of any rescue treatment after EoT (if applicable)
Disability progression
Other measures (1)
Key secondary endpoints (sEP)
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: 1. ≥ 18 years Exclusion: 1. Primary (PPMS) or secondary progressive MS (SPMS)
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To prove the superiority of immunoadsorption over a 2nd course of methylprednisolone as an escalating treatment of steroid refractory relapses in RRMS and CIS.
Papers
Loading reviews and guidelines…
History
Started
Feb 2018